This is the single most important section for anyone weighing the risks of BPC-157, and the honest answer is uncomfortable: there are zero completed Phase III human clinical trials for BPC-157, and the peptide has never received marketing approval from any major regulator
The European Food Safety Authority (EFSA) has set an adequate intake (AI) of 4.0 g/day for adults (EFSA, 2015)
It neutralizes free radicals that can damage skin cells and contribute to aging, dark spots, and uneven skin tone
PD is the second most common NDD and is characterized by progressive loss of dopaminergic and specific non-dopaminergic neurons and the presence of Lewy bodies, which mainly consist of abnormally aggregated -synuclein
Notably, while comprehensive, peer-reviewed studies are still limited, early non-peer-reviewed survey data suggest a significant reduction in grocery expenditures, with households using GLP-1 medications spending approximately 5% less compared to similar non-user households (Hristakeva et al., 2024)
Do not hold it